Opendata, web and dolomites

RESTORE SIGNED

NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESTORE project word cloud

Explore the words cloud of the RESTORE project. It provides you a very rough idea of what is the project "RESTORE" about.

multidisciplinary    traumatic    dendritic    sclerosis    neurodegeneration    therapeutic    nl    neuronal    data    pathogens    autoreactive    center    clinical    cure    safely    500    reactions    drive    ger    first    approvals    practicality    thereby    reducing    efforts    chronic    collaborative    renewal    tolerance    antigen    suffering    patient    outcome    innovative    neurodegenerative    healthcare    safety    mri    balance    efficacy    coordinated    therapy    context    self    people    compare    place    restoring    remaining    adults    correlates    assaults    lives    single    protective    biobanking    repair    regulatory    centralized    central    inflammatory    immunomonitoring    centers    neurological    multiple    radiological    proof    nervous    cell    trials    inflammation    countries    ms    es    hypothesize    disease    disabling    bm1305    young    toldc    clinic    action    safeguarding    breakthrough    cancer    immunity    additional    monitoring    cells    network    consented    untreatable    patients    damaging    immune    inducing    team    joins    accessibility    restore    capacity   

Project "RESTORE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT ANTWERPEN 

Organization address
address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000
website: www.ua.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.h2020restore.eu/
 Total cost 5˙357˙032 €
 EC max contribution 5˙357˙032 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) coordinator 911˙176.00
2    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 1˙170˙212.00
3    Stichting Sanquin Bloedvoorziening NL (Amsterdam) participant 911˙250.00
4    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 660˙056.00
5    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 625˙000.00
6    ICOMETRIX NV BE (LEUVEN) participant 530˙500.00
7    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 363˙837.00
8    STICHTING LYGATURE NL (UTRECHT) participant 185˙000.00

Map

 Project objective

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.

 Deliverables

List of deliverables.
Certificates of clinical training Documents, reports 2019-08-30 14:59:36

Take a look to the deliverables list in detail:  detailed list of RESTORE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Willekens B, Presas-Rodríguez, Mansilla M, Derdelinckx J, Lee W-P, Nijs G, De Laere M, Wens I, Cras P, Parizel PM, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye M, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, López-Díaz de Cerio A, Inogés S, Prósper F, Kip A, Verheij H, Gross CC, Wiendl H, van Ham SM, ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z,
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
published pages: , ISSN: 2044-6055, DOI:
BMJ Open accepted for publication 23/7/2 2019-09-05
2018 Barbara Willekens, Nathalie Cools
Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis
published pages: 401-410, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0518-4
CNS Drugs 32/5 2019-09-05
2019 Anja ten Brinke, Marc Martinez-Llordella, Nathalie Cools, Catharien M. U. Hilkens, S. Marieke van Ham, Birgit Sawitzki, Edward K. Geissler, Giovanna Lombardi, Piotr Trzonkowski, Eva Martinez-Caceres
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective
published pages: , ISSN: 1664-3224, DOI: 10.3389/FIMMU.2019.00181
Frontiers in Immunology 10 2019-09-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESTORE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESTORE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More